This commissioned review article was subject to full peer-review.
Review article: stem cell therapies for inflammatory bowel disease – efficacy and safety
Article first published online: 19 AUG 2010
© 2010 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 32, Issue 8, pages 939–952, October 2010
How to Cite
García-Bosch, O., Ricart, E. and Panés, J. (2010), Review article: stem cell therapies for inflammatory bowel disease – efficacy and safety. Alimentary Pharmacology & Therapeutics, 32: 939–952. doi: 10.1111/j.1365-2036.2010.04439.x
- Issue published online: 26 SEP 2010
- Article first published online: 19 AUG 2010
- Publication data Submitted 24 June 2010 First decision 27 July 2010 Resubmitted 28 July 2010 Accepted 29 July 2010
Aliment Pharmacol Ther 2010; 32: 939–952
Background Drugs available for the treatment of inflammatory bowel disease fail to induce and maintain remission in a significant number of patients.
Aim To assess the value of stem cell therapies for treatment of inflammatory bowel disease based on published studies.
Methods Publications were identified through a MEDLINE search using the Medical Subject Heading terms: inflammatory bowel diseases, or Crohn’s disease, or ulcerative colitis, and stem cell, or stromal cell or transplant.
Results Haematopoietic stem cell therapy as a primary treatment for inflammatory bowel disease was originally supported by animal experiments, and by remissions in patients undergoing transplant for haematological disorders. Later, transplantation specifically performed for patients with refractory Crohn’s disease showed long-lasting clinical remission and healing of inflammatory intestinal lesions. Use of autologous nonmyeloablative regimens and concentration of the procedures in centres with large experience are key in reducing treatment-related mortality. Initial trials of mesenchymal stem cell therapy with local injection in Crohn’s perianal fistulas had positive results.
Conclusions Autologous haematopoietic stem cell transplant changes the natural course of Crohn’s disease, and may be a therapeutic option in patients with refractory disease if surgery is not feasible due to disease location or extension.